Yasmin Korzets Ceder1, Eyal Fenig1,2, Aron Popvtzer1,2, Nir Peled1,2, Mordechai R Kramer2,3, Milton Saute2,4, Dima Bragilovsky1, Tzippy Schochat5, Aaron M Allen6,7. 1. Institute of Oncology, Davidoff Center, Rabin Medical Center, Petach Tikva, Israel. 2. Sackler Faculty of Medicine, Tel-Aviv University, Tel Aviv, Israel. 3. Division of pulmonology, Rabin Medical Center, Petach Tikva, Israel. 4. Department of Cardiothoracic Surgery, Rabin Medical Center, Petach Tikva, Israel. 5. Research and statistics unit, Rabin Medical Center, Petach Tikva, Israel. 6. Institute of Oncology, Davidoff Center, Rabin Medical Center, Petach Tikva, Israel. ahron.alon@gmail.com. 7. Sackler Faculty of Medicine, Tel-Aviv University, Tel Aviv, Israel. ahron.alon@gmail.com.
Abstract
BACKGROUND: SBRT is standard therapy for early stage lung cancer. Toxicity in central tumors has been a concern. RTOG 0813 showed that central SBRT is safe and effective. We report our experience with central SBRT. METHODS: We reviewed the records of patients treated with SBRT for central lung tumors (< 2 cm of the carina). Patients included primary lung cancer and recurrence following surgery and\ or conventional radiotherapy. All patients underwent 4DCT simulation and treatment planning was done with IMRT or VMAT techniques. Dose to the PTV was prescribed to the 95% isodose line. RESULTS: Seventy patients, between 5/09 and 4/13, were treated. Patients had early non-small cell lung cancer (n = 13) or locally recurrent lung cancer (n = 29) and pulmonary oligometastases (n = 28). Fifty-seven percent of the patients received BED of 132 with a schedule of 60Gy in 12 Gy fractions. Median follow up time was 18.3 months, 4/70 patients experienced local failure (6%). Median OS for the whole cohort was 4.6 years (CI 3-7 years). Ten patients had grade 1-2 radiation pneumonitis. One patient developed fatal bronchial bleeding. CONCLUSIONS: SBRT for central tumors is safe and effective in patients with central disease, reiradiation, recurrence following surgery and in oligometastes.
BACKGROUND:SBRT is standard therapy for early stage lung cancer. Toxicity in central tumors has been a concern. RTOG 0813 showed that central SBRT is safe and effective. We report our experience with central SBRT. METHODS: We reviewed the records of patients treated with SBRT for central lung tumors (< 2 cm of the carina). Patients included primary lung cancer and recurrence following surgery and\ or conventional radiotherapy. All patients underwent 4DCT simulation and treatment planning was done with IMRT or VMAT techniques. Dose to the PTV was prescribed to the 95% isodose line. RESULTS: Seventy patients, between 5/09 and 4/13, were treated. Patients had early non-small cell lung cancer (n = 13) or locally recurrent lung cancer (n = 29) and pulmonary oligometastases (n = 28). Fifty-seven percent of the patients received BED of 132 with a schedule of 60Gy in 12 Gy fractions. Median follow up time was 18.3 months, 4/70 patients experienced local failure (6%). Median OS for the whole cohort was 4.6 years (CI 3-7 years). Ten patients had grade 1-2 radiation pneumonitis. One patient developed fatal bronchial bleeding. CONCLUSIONS:SBRT for central tumors is safe and effective in patients with central disease, reiradiation, recurrence following surgery and in oligometastes.
Authors: Puneeth Iyengar; Brian D Kavanagh; Zabi Wardak; Irma Smith; Chul Ahn; David E Gerber; Jonathan Dowell; Randall Hughes; Ramzi Abdulrahman; D Ross Camidge; Laurie E Gaspar; Robert C Doebele; Paul A Bunn; Hak Choy; Robert Timmerman Journal: J Clin Oncol Date: 2014-10-27 Impact factor: 44.544
Authors: Bryan P Rowe; Daniel J Boffa; Lynn D Wilson; Anthony W Kim; Frank C Detterbeck; Roy H Decker Journal: J Thorac Oncol Date: 2012-09 Impact factor: 15.609
Authors: Tommy Sheu; John V Heymach; Stephen G Swisher; Ganesh Rao; Jeffrey S Weinberg; Reza Mehran; Mary Frances McAleer; Zhongxing Liao; Thomas A Aloia; Daniel R Gomez Journal: Int J Radiat Oncol Biol Phys Date: 2014-09-09 Impact factor: 7.038
Authors: Jason W D Hearn; Gregory M M Videtic; Toufik Djemil; Kevin L Stephans Journal: Int J Radiat Oncol Biol Phys Date: 2014-07-10 Impact factor: 7.038
Authors: Brandon T Mullins; Dominic T Moore; M Patricia Rivera; Lawrence B Marks; Jason Akulian; Kevin A Pearlstein; Kyle Wang; Allen C Burks; Ashley A Weiner Journal: J Thorac Dis Date: 2021-02 Impact factor: 2.895
Authors: Sondos Zayed; Hanbo Chen; Emma Ali; George B Rodrigues; Andrew Warner; David A Palma; Alexander V Louie Journal: Int J Radiat Oncol Biol Phys Date: 2020-06-13 Impact factor: 7.038